Stay updated with breaking news from Zerun Bio. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
DUBLIN--(BUSINESS WIRE)--The "COVID-19 - Competitive Landscape, 2023" report has been added to ResearchAndMarkets.com's offering.This "COVID-19 Competitive landscape 2023" report provides comprehensive insights about 400+ companies and 500+ drugs in COVID-19 Competitive landscape. It covers the therapeutics assessme...
Chinese vaccine developer Shanghai Zerun Biotechnology and its parent company Walvax will receive extra funding to advance the early stage clinical trials of a Covid-19 shot against all variants of concern, including Omicron.
Here's a look at the news highlights from Asean countries in the Star-AseanPlus section for Tuesday (Feb 8)
Global foundation CEPI will invest another US$8.15 million to support phase 1 and 2 trials of the shot as well as a vaccine for the original coronavirus strain.